Published in Blood on March 18, 2009
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma (2014) 1.40
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact (2009) 1.08
Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol (2011) 1.08
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst (2012) 1.04
Systems biology of human benzene exposure. Chem Biol Interact (2009) 0.99
Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev (2011) 0.87
Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.87
Current knowledge and future research directions in treatment-related second primary malignancies. EJC Suppl (2014) 0.85
Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors. Cancer (2014) 0.85
The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci (2014) 0.85
Neurexophilin 1 suppresses the proliferation of hematopoietic progenitor cells. Blood (2011) 0.85
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biol Blood Marrow Transplant (2016) 0.79
Temozolomide-induced myelodysplasia. Adv Hematol (2010) 0.79
Therapy-related myelodysplastic syndrome: models and genetics. Biol Blood Marrow Transplant (2009) 0.78
Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol (2011) 0.77
Personalized Cancer Risk Assessments for Space Radiation Exposures. Front Oncol (2016) 0.75
In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics. Expert Opin Drug Discov (2016) 0.75
Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma. Rare Tumors (2015) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Inference of population structure using multilocus genotype data. Genetics (2000) 147.76
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
The International HapMap Project. Nature (2003) 73.65
Genomic control for association studies. Biometrics (1999) 64.39
Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics (2003) 53.11
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 43.16
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 18.98
Large-scale genotyping of complex DNA. Nat Biotechnol (2003) 10.00
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Algorithms for large-scale genotyping microarrays. Bioinformatics (2003) 2.66
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc Natl Acad Sci U S A (1997) 2.53
Therapy-related myeloid leukemia. Semin Oncol (2008) 2.36
Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer (2005) 2.30
Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia (2008) 2.29
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array. Cancer Res (2005) 2.22
Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta (1998) 2.17
The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans. J Biol Chem (1996) 2.15
Application of genome-wide single nucleotide polymorphism typing: simple association and beyond. PLoS Genet (2006) 2.02
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood (1981) 1.62
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J (2008) 1.48
New complexities in the genetics of stuttering: significant sex-specific linkage signals. Am J Hum Genet (2006) 1.46
Therapy-related myeloid leukemia. Hematol Oncol Clin North Am (1996) 1.44
Etiology and management of therapy-related myeloid leukemia. Hematology Am Soc Hematol Educ Program (2007) 1.39
Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A (2001) 1.39
The incidence of secondary leukemias. Haematologica (1999) 1.36
Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood (2001) 1.27
Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol (2007) 1.23
Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood (2002) 1.18
High density SNP association study of a major autism linkage region on chromosome 17. Hum Mol Genet (2007) 1.13
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers. Cancer Res (2006) 1.06
Inositol pentakisphosphate mediates Wnt/beta-catenin signaling. J Biol Chem (2007) 1.03
The roles of Groucho/Tle in left-right asymmetry and Kupffer's vesicle organogenesis. Dev Biol (2006) 0.98
A new Groucho TLE4 protein may regulate the repressive activity of Pax5 in human B lymphocytes. Immunology (2002) 0.97
Association between the ACCN1 gene and multiple sclerosis in Central East Sardinia. PLoS One (2007) 0.97
Hex acts with beta-catenin to regulate anteroposterior patterning via a Groucho-related co-repressor and Nodal. Development (2006) 0.93
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep (2007) 0.93
RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. Oncogene (2006) 0.93
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia (2004) 0.86
p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res (2002) 0.85
Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia. Oncogene (2006) 0.81
Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol (2002) 0.78
Finding the missing heritability of complex diseases. Nature (2009) 67.95
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (2009) 25.61
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med (2005) 14.59
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet (2010) 10.75
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The allelic architecture of human disease genes: common disease-common variant...or not? Hum Mol Genet (2002) 10.08
The global circulation of seasonal influenza A (H3N2) viruses. Science (2008) 10.05
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science (2009) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol (2005) 7.88
Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med (2005) 6.83
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A (2012) 6.27
Transmission of equine influenza virus to dogs. Science (2005) 6.11
SCAN: SNP and copy number annotation. Bioinformatics (2009) 5.96
Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis (2002) 5.92
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol (2002) 5.74
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science (2002) 5.47
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep (2007) 5.32
Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis (2007) 5.21
Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 5.19
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2004) 5.00
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet (2008) 4.37
A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A (2007) 4.35
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol (2012) 4.34
Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet (2011) 4.26
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet (2005) 4.15
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol (2011) 4.10
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet (2008) 4.01
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Global concerns regarding novel influenza A (H7N9) virus infections. N Engl J Med (2013) 3.88
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A (2007) 3.77
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol (2006) 3.50
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2005) 3.50
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
Genetic architecture of transcript-level variation in humans. Am J Hum Genet (2008) 3.36
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2002) 3.27
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity. Virology (2011) 3.19
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood (2010) 3.15
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol (2007) 3.04
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00